FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 381-86	SERIAL NO. Unassigned	0
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Thomas Teufel		(63597 (63597)
(Use several sheets if necessary)	FILING DATE Herewith	GROUP Unassigned	1684

U.S. PATENT DOCUMENTS

		0.5.	PATENT DUCUMENTS			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
Ø	4,816,397	03/28/89	Boss, et al.			
	5,196,446	03/23/93	Levitzki, et al.			
	5,550,114	08/27/96	Strayer			,
	5,646,153	07/08/97	Spada, et al.			
	5,656,655	08/12/97	Spada, et al.			
	5,679,683	10/21/97	Bridges, et al.			
	5,789,427	08/04/98	Chen, et al.			
	5,851,999	12/22/98	Ullrich, et al.			
	5,861,499	01/19/99	Rockwell, et al.			
	5,869,465	02/09/99	Morgan, Jr. et al.	•		
	5,914,269	06/22/99	Bennett, et al.			
	5,925,566	07/20/99	Davis, et al.			
	5,955,311	09/21,99	Rockwell, et al.			
<b>√</b>	6,004,967	12/21/99	McMahon, et al.			

EXAMINER

In 6

DATE CONSIDERED

5/20/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 381-86	SERIAL NO. Unassigned	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Thomas Teufel		
(Use several sheets if necessary)	FILING DATE Herewith	GROUP Unassigned	

# FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL			CLASS	SUB CLASS	TRANSLATION			
	ITTAL NOMBER	CLASS			NO			
P	/	PCT/AU99/00 420	05/31/99	Europe				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies," Journal of Immunological Methods,# 231:11-23 (1999).  Jost, et al., "A Central Role of Bcl-X <sub>L</sub> in the Regulation of Keratinocyte Survival by Autocrine EGFR Ligands," The Journal of Investigative Dermatology, # 112:443-449 (1999).  Kao, et al., "Comparison of the Effect of 8-Methoxypsoralen (8-MOP) plus UVA (PUVA) on Human Melanocytes in Vitiligo Vulgaris and In Vitro," The Journal of Investigative Dermatology, # 98(5):734-740 (1992).  Rikimaru, et al., "Correlation between hyperproliferation and suprabasal integrin expression in human epidermis reconstituted in culture," Experimental Dermatology, #6:214-221 (1997)  Gottlieb, et al., "Detection of Transforming Growth Factor α in Normal, Malignant, and		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
Autocrine EGFR Ligands," The Journal of Investigative Dermatology, # 112:443-449 (1999).  Kao, et al., "Comparison of the Effect of 8-Methoxypsoralen (8-MOP) plus UVA (PUVA) on Human Melanocytes in Vitiligo Vulgaris and In Vitro," The Journal of Investigative Dermatology, # 98(5):734-740 (1992).  Rikimaru, et al., "Correlation between hyperproliferation and suprabasal integrin expression in human epidermis reconstituted in culture," Experimental Dermatology, #6:214-221 (1997)  Gottlieb, et al., "Detection of Transforming Growth Factor α in Normal, Malignant, and Hyperproliferative Human Keratinocytes," Brief Definitive Report, # 167:670-675 (1998).  Fransson et al., "Epidermal growth in the skin equivalent," Archives of Dermatological Research, # 284:343-348 (1992)  Castelijns, et al., "The epidermal phenotype during initiation of the psoriatic lesion in the symptomless margin of relapsing psoriasis," Journal of the American Academy of	<u>(M</u>	
(PUVA) on Human Melanocytes in Vitiligo Vulgaris and In Vitro," The Journal of Investigative Dermatology, # 98(5):734-740 (1992).  Rikimaru, et al., "Correlation between hyperproliferation and suprabasal integrin expression in human epidermis reconstituted in culture," Experimental Dermatology, #6:214-221 (1997)  Gottlieb, et al., "Detection of Transforming Growth Factor α in Normal, Malignant, and Hyperproliferative Human Keratinocytes," Brief Definitive Report, # 167:670-675 (1998).  Fransson et al., "Epidermal growth in the skin equivalent," Archives of Dermatological Research, # 284:343-348 (1992)  Castelijns, et al., "The epidermal phenotype during initiation of the psoriatic lesion in the symptomless margin of relapsing psoriasis," Journal of the American Academy of		Autocrine EGFR Ligands," The Journal of Investigative Dermatology, # 112:443-449
expression in human epidermis reconstituted in culture," Experimental Dermatology, #6:214-221 (1997)  Gottlieb, et al., "Detection of Transforming Growth Factor α in Normal, Malignant, and Hyperproliferative Human Keratinocytes," Brief Definitive Report, # 167:670-675 (1998).  Fransson et al., "Epidermal growth in the skin equivalent," Archives of Dermatological Research, # 284:343-348 (1992)  Castelijns, et al., "The epidermal phenotype during initiation of the psoriatic lesion in the symptomless margin of relapsing psoriasis," Journal of the American Academy of		(PUVA) on Human Melanocytes in Vitiligo Vulgaris and In Vitro," The Journal of
Hyperproliferative Human Keratinocytes," Brief Definitive Report, # 167:670-675 (1998).  Fransson et al., "Epidermal growth in the skin equivalent," Archives of Dermatological Research, # 284:343-348 (1992)  Castelijns, et al., "The epidermal phenotype during initiation of the psoriatic lesion in the symptomless margin of relapsing psoriasis," Journal of the American Academy of		expression in human epidermis reconstituted in culture," Experimental Dermatology,
Research, # 284:343-348 (1992)  Castelijns, et al., "The epidermal phenotype during initiation of the psoriatic lesion in the symptomless margin of relapsing psoriasis," Journal of the American Academy of		Gottlieb, et al., "Detection of Transforming Growth Factor α in Normal, Malignant, and Hyperproliferative Human Keratinocytes," <i>Brief Definitive Report</i> , # 167:670-675 (1998).
symptomless margin of relapsing psoriasis," Journal of the American Academy of		
		symptomless margin of relapsing psoriasis," Journal of the American Academy of
EXAMINER OL DATE CONSIDERED 52002	EXAMINER	OL DATE CONSIDERED 5/20/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. 381-86	SERIAL NO. Unassigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICANT Thomas Teufel	
	(Use several	sheets if necessary)	FILING DATE Herewith	GROUP Unassigned
	<del> ,</del>			
20	_		Factors and Effects of	: Comparison with Normal Skin an Antibody to the EGF Receptor,"
	/	Elder, et al., "Human Severe Co T Cell Tyrosine Kinase," Science		ency Due to a Defect in ZAP-70, a
	1	Dvir, et al., "The Inhibition of I Tyrphostin Tyrosin Kinase Blo	<del>-</del>	•
	/			vels in psoriatic skin and stimulates Natl. Acad. Sci. USA, # 86:6367-
		Fry, et al., "A Specific Inhibitor Kinase," <i>Science</i> , # 265:1093-1	<del>-</del>	vth Factor Receptor Tyrosine
				nto the role of TGF-α during—— Development, # 5:714-727 (1991).
	_	Gazit, et al., "Tyrphostins. 6. D Inhibitors of EGF Receptor Tyr # 39:4905-4911 (1996).		ononitrile Tyrphostins: Potent  Journal of Medicinal Chermistry,
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Ben-Bassat, et al., "Tyrphostins  Experimental Dermatology, # 4		f psoriatic keratinocytes,"
	/	Panek, et al., "In Vitro Pharmac Nanomolar Potent and Broadly Pharmacology and Experiment	Active Protein Tyrosin	e Kinase Inhibitor," The Journal of

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

DATE CONSIDERED

**EXAMINER** 

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 381-86	SERIAL NO. Unassigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Thomas Teufel	
(Use several sheets if necessary)	FILING DATE Herewith	GROUP Unassigned
Abgenix, Inc. Press Release, "A Psoriasis," April 3, 2000,	bgenix Initites Phase II	I Clinical Trial with ABX-IL8 in

**EXAMINER** 

DATE CONSIDERED

5/20/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

# SUPPLEMENT INFORMATION DISCLOSION STATEMENT BY APPLICANT PTO-1449

ATTY. DOCKET NO.

11245/48601

APPLICANT
T. TEUFEL

FILING DATE
August 9, 2000

SERIAL NO.
09/635,974

RECEIVED

GROUP
AFR 2 5 2002

TECH CENTER 1600/25

## **U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	4,943,533	July 24, 1990	Mendelsohn et al.			
		<del> </del>		-		

### FOREIGN PATENT DOCUMENTS

EXAMINER	DOCUMENT					TRANSL	ATION
INITIAL	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
013	WO 99/60023	November 25, 1999	PCT				

### OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
0	/	Huang et al., "Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck", Cancer Research, April 15, 1999, vol. 59, pp. 1935-1940
60	/	Laskin et al., "Psoralens potentiate ultraviolet light-induced inhibition of epidermal growth factor binding", PNAS, November 1986, vol. 83, pp. 8211-8215

EXAMINER DATE CONSIDERED 5 70 07.

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

465641

COPY OF PAPERS ORIGINALLY FILED